Combination therapy reduced HER2-positive breast cancers
SAN ANTONIO — A combination of lapatinib, trastuzumab and paclitaxel significantly improved tumor response rates than either agent alone among patients with HER2-positive breast cancers, according to data presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 8-12. Full results were presented at the symposium during a press briefing on Dec. 10, 2010, at 8:00 a.m. CT.
Reporters who cannot attend in person can participate using the following call-in information:
U.S. and Canada: (888) 282-7404
International: (706) 679-5207
Access Code: ...






